Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW ACN Newswire

Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW

February 3, 2023
SYDNEY, AU, Feb 3, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors.Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).The company recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases.In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.Novotech CEO Dr. John Moller said: "Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, selected for the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data report:Evolution of Clinical Trials in the Asia Pacific Region Compared to the US and the EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech (Novotech-CRO.com)Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference ACN Newswire

Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

September 15, 2022
SYDNEY, AU, Sep 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference.Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific. The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC. In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW. Blood cancers (ALL, NHL, DLBCL, lymphomas), solid tumors, viral infections, liver and gastrointestinal tract cancers are the top indications in China-based cell & gene therapy trials between 2016 and 2021.Watch our recent Endpoints News webinar for more information:EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-Thttps://novotech-cro.com/webinars/evolution-cell-gene-therapy-china-case-universal-car-tThe award was presented to Novotech during the 6th Cell & Gene Therapy World Asia 2022 conference (14th - 15th September) at the Sheraton Towers, Singapore.Novotech CEO Dr. John Moller said, "We are extremely pleased our team has been recognized with this prestigious award at the 6th Cell & Gene Therapy World Asia 2022 conference. Cell & gene therapy is driving recent innovations in biotech and it is an honour to be recognized as the CRO at the forefront in Asia-Pacific supporting this vital clinical research. Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently also been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data reports here:EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech Novotech is the leading Asia-Pacific centered, globally capable, biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center JCN Newswire

Hitachi: Proton Therapy Provider Chosen for UW Health Eastpark Medical Center

July 27, 2022
MADISON, WI, Jul 27, 2022 - (JCN Newswire via SEAPRWire.com) - UW Health has selected Hitachi, Ltd. (TSE:6501, "Hitachi") to provide the infrastructure to support proton therapy at UW Health Eastpark Medical Center.Proton therapy equipment combined with Hitachi's 360° rotating gantry and Leo's upright systemHitachi will provide equipment and technology to support UW Health's traditional proton therapy room equipped with spot scanning irradiation technology, a 360 degrees rotating gantry with cone-beam CT(1), and Real-time image Gated Proton Therapy (RGPT)(2), as well as the revolutionary upright proton therapy coming to UW Health from Leo Cancer Care, according to Dr. Paul Harari, radiation oncologist, UW Health, and chair of the Department of Human Oncology, University of Wisconsin School of Medicine and Public Health."We're excited to reach this important milestone to offer state-of-the-art proton therapy at UW Health," Harari said. "It's particularly significant in linking together Hitachi, an experienced proton provider, a new technology from Leo Cancer Care and a major academic medical center with a track record of cutting-edge technology development and implementation, all working together on behalf of cancer patients."UW Health worked closely with Proton International, a consulting organization dedicated to connecting hospitals and physicians with proton specialists and developing state- of-the-art proton therapy facilities."The team at Proton International is excited to help UW Health bring this important technology to the people of Wisconsin," said Chris Chandler, CEO, Proton International. "We also believe that the Leo Cancer Care's upright treatment room is an important innovation that will help patients and we look forward to working on the project implementation.""We feel privileged that we were selected by UW Health, one of the top healthcare institutions in the nation," said Hiroyuki Itami, General Manager of the Smart Therapy Division of Hitachi. "We are also thrilled to partner with Leo Cancer Care and Proton International to achieve a new innovative proton therapy solution. Hitachi is committed to supporting people's quality of life through technical advancement."UW Health broke ground on Eastpark Medical Center in May and it is expected to open in 2024.(1) Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.(2) RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech and Endpoints Present “Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T” ACN Newswire

Novotech and Endpoints Present “Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T”

July 18, 2022
SYDNEY, Jul 18, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China - the current landscape and future opportunities. China now represents 60% of clinical development in CAR-T therapy development globally. This webinar will cover learnings to date and future opportunities.Specific areas covered include:- The current landscape for biotech CAR-T therapy research in China- CAR-T clinical development in China: key areas of focus- Potential opportunities related to universal CAR-T cell therapy development- The challenges of allogeneic CAR-T cell therapyRegister here: https://webinars.endpts.com/evolution-of-cell-gene-therapy-in-china-the-case-for-universal-car-t/Webinar Date:- July 19, 2022- 1:00 pm - 2:00 pm EDTModerator:- Arsalan Arif, Founder and Publisher Endpoints News Presenters:- Dr. Jie Cheng, Chief Medical Officer Bioheng- Dr. Vivian Gu, Vice President, Clinical Development & Regulatory, CMO, Novotech China- Dr Kai Xue, Associate Professor, Department of Haematology, Ruijin Hospital, Shanghai, ChinaAccording to Global Data: "Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites." Novotech CEO Dr. John Moller said: "The Asia-Pacific is the fastest-growing clinical trial destination for biotechs, with China being the leading location for new trials followed by the US. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, also offers its biotech clients clinical services in the US to support later phase global studies. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years. About Novotech Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More